Syndax Pharmaceuticals (SNDX) Q3 2024 Earnings
SNDX·Reported November 5, 2024·After market close
Syndax Pharmaceuticals reported Q3 2024 revenue of $12.5M, missed analyst consensus of $115.2M by $102.7M. Diluted EPS came in at $-0.98, beat the $-1.13 consensus by $0.15.
Revenue
$12.5Mmissed by $102.7M
Consensus: $115.2MDiluted EPS
$-0.98beat by $0.15
Consensus: $-1.13
Financial Snapshot
Trailing eight quarters through Q3 2024
Q3 2024 Earnings FAQ
Common questions about Syndax Pharmaceuticals's Q3 2024 earnings report.
Syndax Pharmaceuticals (SNDX) reported Q3 2024 earnings on November 5, 2024 after market close.
Syndax Pharmaceuticals reported revenue of $12.5M and diluted EPS of $-0.98 for Q3 2024.
Revenue missed the consensus estimate of $115.2M by $102.7M. EPS beat the consensus estimate of $-1.13 by $0.15.
You can read the 10-Q periodic report (0000950170-24-121439) directly on SEC EDGAR. The filing index links above go to sec.gov.